midazolam with fentanyl
PreclinicalSmall molecule
midazolam with fentanyl is one of 37 small molecule programs targeting Atrial Fibrillation. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
137 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Calquence
AstraZenecaPreclinical
Rituxan
RochePreclinical
Coumadin
AAbbott
Preclinical
Brukinsa
BBeOne Medicines
Preclinical
Imbruvica
PPharmacyclics LLC.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for midazolam with fentanyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYonsei University